US FDA rejects Eisai/Astex drug for AML indication
This article was originally published in Scrip
Investors obviously had been preparing themselves for a rejection from the US FDA for Eisai's and Astex Pharmaceuticals' nucleoside metabolic inhibitor Dacogen (decitabine) as a treatment for acute myeloid leukaemia (AML) in older adults, with shares of the latter company first falling 3.8% in morning trading on 7 March, before the stock regained its composure, even getting a bump of 2.7%, or 5 cents.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.